Illumina sees revenue increases for Q1 as net income slips

By staff writers

May 6, 2022 -- Strong growth across multiple business units helped DNA sequencing developer Illumina report revenue increases for the first quarter of fiscal 2022 (end-April 3, 2022). The company also reported that orders hit a record level.

Illumina said revenue for the quarter was $1.2 billion, up 12% from $1.1 billion reported in the same quarter in the previous year. Illumina is also reiterating its full-year revenue guidance of 14% to 16% growth from the 2021 fiscal year.

The company's net income for the quarter was $86 million, down compared to a net income of $147 million in the second quarter of 2021.

The company said it saw strong momentum for its oncology therapy selection, genetic disease testing, and pathogen surveillance, including what it called record total orders. Illumina noted that its most recent numbers include revenues from Grail, which it acquired in August 2021.

Illumina brings whole-genome sequencing to German hospital
Illumina has signed an agreement with Hannover Medical School in Germany to assess the use of rapid whole-genome sequencing (rWGS) in critically ill children...
Illumina hits Guardant with lawsuit over trade secrets
Illumina has hit Guardant Health with a lawsuit alleging Guardant and its founders Helmy Eltoukhy and AmirAli Talasaz misappropriated Illumina's trade...
Illumina releases in vitro cancer profiling test
Illumina has launched TruSight Oncology Comprehensive, a test that examines tumor genes and biomarkers to define the specific molecular profile of a patient's...
Illumina to collaborate with Japan's National Cancer Center
Illumina and Japan's National Cancer Center have announced a collaboration that will use Illumina's DNA sequencing assay TruSight Oncology 500 ctDNA to...
Agendia, Illumina partner on genomic testing for breast cancer
Precision oncology firm Agendia has announced a multiyear partnership with Illumina to co-develop IVD tests for oncology testing. The companies aim to...

Copyright © 2022

Last Updated mp 5/6/2022 12:08:29 PM